Open Heart

JUNE 9, 2022

Background This review aimed to compare the relative effectiveness of different exercise-based cardiac rehabilitation (ExCR) delivery modes (centre-based, home-based, hybrid and technology-enabled ExCR) on key heart failure (HF) outcomes: exercise capacity, health-related quality of life (HRQoL), HF-related hospitalisation and HF-related mortality.

Quality of Life 52

Quality of Life Cardiac Rehabilitation Exercise Heart Failure 52

Circulation: Heart Failure

JANUARY 8, 2025

Secondary outcomes were rehospitalizations, change in 6-minute walk test distance, change in Kansas City Cardiomyopathy Questionnaire, and change in EuroQol questionnaire scores 1 year after LVAD.RESULTS:Our study included 10 310 patients with complete clinical, echocardiographic, and functional capacity profiles. versus +0.17;P=0.001),

Quality of Life 76

Quality of Life Heart Failure Pulmonary Cardiomyopathy 76

Circulation: Cardiovascular Interventions

FEBRUARY 10, 2025

Hypertrophic cardiomyopathy is a common but underrecognized cardiac disorder characterized by a heterogenous phenotype that includes increased left ventricular thickness, outflow obstruction, diastolic dysfunction, and arrhythmia. Hypertrophic cardiomyopathy is often heritable and associated with pathogenic variants in sarcomeric genes.

Cardiomyopathy 40

Cardiomyopathy Quality of Life Bicuspid/Mitral Cardiovascular Interventions 40

Cardiology Update

AUGUST 4, 2024

The primary outcome is the GDMT prescription rate score, with secondary outcomes covering the time to full GDMT optimization, patient and clinician satisfaction, time spent on healthcare, and the Kansas City Cardiomyopathy Questionnaire. The results of this trial are eagerly anticipated.

Heart Failure 119

Heart Failure ACE Inhibitor COVID-19 Quality of Life 119

Open Heart

JANUARY 18, 2024

Currently, there is no optimal revascularisation strategy for patients with ischaemic cardiomyopathy despite suggestions that coronary artery bypass graft (CABG) may be superior to medical therapy in improving survival. The improvement in quality of life and distance at the 6MWT in both groups was significant (p<0.001).

Coronary Artery Bypass Graft 94

Coronary Artery Bypass Graft Quality of Life Public Health Heart Failure 94

Journal of the American Heart Association

MARCH 7, 2025

BackgroundCardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. Journal of the American Heart Association, Ahead of Print. Additionally, we included data from regulatory agencies.

Cardiomyopathy 45

Cardiomyopathy Quality of Life Atrial Fibrillation Pharmacology 45

DAIC

MAY 20, 2024

Geisinger is at the forefront of research and technological advancements that allow for better patient outcomes and improvements in their quality of life.” Cardiac amyloidosis is caused by protein buildup between the muscle cells of the heart, increasing the thickness of the heart.

Cardiomyopathy 52

Cardiomyopathy Quality of Life Heart Failure Blood Pressure 52

Journal of the American Heart Association

DECEMBER 24, 2024

BackgroundIn obstructive hypertrophic cardiomyopathy, myectomy improves symptoms, quality of life, and left ventricular (LV) outflow tract gradients. P=0.24) or Kansas City Cardiomyopathy Questionnaire summary score change (r=0.02,P=0.85), P=0.85), whereas it was significantly associated with change inE/e (r=0.29,P=0.003).ConclusionsIn

Cardiomyopathy 40

Cardiomyopathy Quality of Life 40

Circulation: Cardiovascular Quality & Outcomes

FEBRUARY 3, 2025

The interview guide addressed symptoms, physical and social functioning, and quality of life concepts of the KCCQ, as well as other potential TR symptoms not represented in the KCCQ. Lower limb edema was also reported by 10 participants.

Tricuspid 40

Tricuspid Quality of Life Cardiomyopathy Circulation 40

American College of Cardiology

SEPTEMBER 30, 2024

Treatment with aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM) was associated with broad clinical efficacy across multiple outcome domains, including rapid and sustained decreases in outflow gradients, meaningful improvements in functional class and quality of life, enhanced exercise capacity, and significant reductions in (..)

Quality of Life 40

Quality of Life Exercise Cardiomyopathy Outcomes 40

Frontiers in Cardiovascular Medicine

FEBRUARY 19, 2024

Laboratory tests and echocardiography confirmed heart failure and hypertrophic cardiomyopathy. Conclusions Although enzyme replacement therapy can significantly improve the quality of life for patients with PD, enhancing mitochondrial function may represent a new therapeutic strategy for treating PD.

Cardiogenic Shock 59

Cardiogenic Shock Quality of Life Heart Failure Laboratory 59

Frontiers in Cardiovascular Medicine

OCTOBER 10, 2024

and improved patients’ quality of life scores. The intergroup comparison showed the therapeutic effect of the combination was equivalent in HF caused by myocardial Infarction (MI), dilated cardiomyopathy (DCM) or Valvular Heart Disease (VHD).ConclusionVericiguat

Heart Failure 52

Heart Failure Preserved Ejection Fraction Cardiac Function Quality of Life 52

Open Heart

MAY 8, 2024

to –0.39), 6 min walk distance (mean difference: +109 m (95% CI 105 to 114 m) and quality of life (standardised mean difference: +0.52 (95% CI 0.32 A similar pattern of effects was observed for both ischaemic and non-ischaemic cardiomyopathy.

Heart Failure 52

Heart Failure Quality of Life Outcomes Cardiomyopathy 52

European Journal of Heart Failure

SEPTEMBER 26, 2023

6MWT, 6-min walk test; KCCQ, Kansas City Cardiomyopathy Questionnaire physical domain score; peakVO 2 , peak oxygen consumption; RCT, randomized controlled trial. Secondary endpoints included changes in submaximal exercise capacity and quality of life. m (95% CI 16.9, p  = 0.0124), both after 12 weeks.

Exercise 40

Exercise Heart Failure Quality of Life Cardiomyopathy 40

Dr. Sanjay Gupta

MARCH 6, 2022

Heart failure or cardiac insufficiency has marked negative effects both on quality of life and quantity of life. People with a weak heart do not in general live as long as those with a strong heart and people with a weak heart will in general have a significantly worse quality of life compared to those with a strong heart.

Heart Failure 40

Heart Failure Quality of Life ACE Inhibitor Exercise 40

DAIC

APRIL 9, 2024

The international ARISE-HF trial was designed to test the effectiveness of the investigational drug AT-001 at stabilizing exercise capacity in patients with diabetic cardiomyopathy. Secondary endpoints included change in patients’ overall level of physical activity and in their perception of their symptoms and quality of life.

Heart Failure 52

Heart Failure Diabetes Cardiomyopathy Exercise 52

Circulation

NOVEMBER 11, 2024

p&lt;0.001), and overall Kansas City Cardiomyopathy Questionnaire (KCCQ) score improved by 7.6 Patients experienced significant clinical improvements in New York Heart Association (NYHA) functional class I/II (32.6% to 96.5%, p &lt; 0.001). Six-minute walk test increased by 31.9m(304.3±81.2, p&lt;0.001).

Tricuspid 40

Tricuspid Quality of Life Heart Failure Cardiomyopathy 40

European Journal of Heart Failure

DECEMBER 7, 2023

Patients with increasing obesity have higher right- and left-sided ventricular filling pressures, increased cardiac output (CO), lower 6-min walk distance (6MWD) and worse Kansas City Cardiomyopathy Questionnaire (KCCQ) scores. Echocardiography showed significant left-sided cardiac remodelling. Overall, 60.9% of patients had BMI ≥30 kg/m 2.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Obesity Heart Failure BMI 40

DAIC

APRIL 9, 2024

Maron, MD “Our findings provide enthusiasm that a novel drug therapy with ninerafaxstat may provide nonobstructive HCM patients an opportunity to achieve a better quality of life by decreasing symptom burden and improving exercise capacity,” said Martin S. For more information on hypertrophic cardiomyopathy, visit CardioSmart.org/HCM.

Cardiomyopathy 52

Cardiomyopathy Quality of Life Chest Pain Preserved Ejection Fraction 52

DAIC

MAY 9, 2024

The American College of Cardiology (ACC) and the American Heart Association (AHA) today released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy (HCM). Ommen, MD, FACC , medical director of the Mayo Hypertrophic Cardiomyopathy Clinic and chair of the guideline writing committee.

Cardiomyopathy 52

Cardiomyopathy Pediatrics Quality of Life Sudden Cardiac Death 52

DAIC

MARCH 25, 2025

Effect of finerenone on N-terminal pro-B-type natriuretic peptide in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial during the session "Finerenone: A Promising Addition to the Armamentarium or Merely an Academic Exercise?"

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

Circulation

NOVEMBER 11, 2023

Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 mg or placebo for 52 weeks. mg or placebo for 52 weeks. 5.4,16.1), 8.1 2.7,13.4), 4.6 (-0.6,9.9)

Preserved Ejection Fraction 40

Preserved Ejection Fraction Quality of Life Obesity Heart Failure 40

DAIC

MARCH 8, 2024

million grant awarded to Georgia Tech by the United States Department of Defense Congressionally Directed Medical Research Programs (CDMRP) as part of the agency’s call for the development of less invasive treatment technologies for cardiovascular conditions associated with cardiomyopathy. The research is funded by a four-year, $7.8

Blood Clot 98

Blood Clot Heart Failure Quality of Life Innovation 98

DAIC

APRIL 6, 2024

Surprisingly, a marked improvement in quality of life as measured with KCCQ was observed across all groups—including those who received a placebo procedure, both with HFrEF and HFpEF—suggesting that the metric may not be a reliable indicator for quality-of-life outcomes in this context, Stone said.

Heart Failure 81

Heart Failure Quality of Life Outcomes Preserved Ejection Fraction 81

DAIC

APRIL 6, 2024

Surprisingly, a marked improvement in quality of life as measured with KCCQ was observed across all groups—including those who received a placebo procedure, both with HFrEF and HFpEF—suggesting that the metric may not be a reliable indicator for quality-of-life outcomes in this context, Stone said.

Heart Failure 75

Heart Failure Quality of Life Preserved Ejection Fraction Hospital 75

DAIC

FEBRUARY 15, 2024

According to a written statement, the GenePHIT trial aims to evaluate the safety and efficacy of a single intracoronary infusion of AB-1002 in adults with New York Heart Association (NYHA) Class III Heart Failure and non-ischemic cardiomyopathy who have been medically stable for at least 4 weeks.

Heart Failure 89

Heart Failure Cardiomyopathy Quality of Life Innovation 89

European Journal of Heart Failure

DECEMBER 13, 2023

Dapagliflozin, as compared with placebo, improved the Kansas City Cardiomyopathy Questionnaire scores from baseline to 8 months to a similar extent in patients with and without mild-to-moderate COPD ( p interaction  ≥ 0.63). In addition, dapagliflozin was safe and well-tolerated, irrespective of COPD status.

Preserved Ejection Fraction 75

Preserved Ejection Fraction Heart Failure Pulmonary Quality of Life 75

DAIC

MARCH 25, 2025

Effect of finerenone on N-terminal pro-B-type natriuretic peptide in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial during the session "Finerenone: A Promising Addition to the Armamentarium or Merely an Academic Exercise?"

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

Open Heart

MAY 12, 2023

Kansas City Cardiomyopathy Questionnaire overall summary score assessing quality of life improved from baseline to 30 days after TAVR (67.0±20.6 Valve haemodynamics improved following TAVR (AVA 2.5±0.7 cm 2 , peak velocity 1.9±0.5 m/s and MG 8.4±4.8 mm Hg; p<0.001 for all) and SAVR (AVA 2.0±0.6

Aortic valve 52

Aortic valve Aortic Stenosis TAVR 52

Dr. Sanjay Gupta

MAY 23, 2022

Today’s vlog is on the subject of heart failure and in particular on a special type of pacemaker which can make a significant improvement to the quality of life and length of life in patients with heart failure. length of life? You can download this script as a Hindi translation here. What is heart failure?

Heart Failure 40

Heart Failure Pacemaker Quality of Life ACE Inhibitor 40

Heart 2023 Conference

APRIL 20, 2022

Patients with obstructive hypertrophic cardiomyopathy who underwent surgical myectomy reported improved quality of life.

Pulmonary 52

Pulmonary Hypertension AFIB COVID-19 52

Dr. Sanjay Gupta

MARCH 6, 2022

Pharmacological treatments: These can be divided into 2 groups Medications that improve quality of life (usually by relieving symptoms) and medications that can prolong life. Medications that improve quality of life in heart failure for example include diuretics. I hope you found this useful.

Chronic Disease 40

Chronic Disease Quality of Life Heart Failure Nursing 40

American College of Cardiology

AUGUST 30, 2024

Patients receiving the subcutaneously administered RNA interference therapeutic agent also saw preserved functional capacity and better quality of life, researchers said.

Quality of Life 40

Quality of Life Cardiomyopathy Research Article 40

Circulation

NOVEMBER 17, 2024

Primary endpoints: tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score(KCCQ-CSS). n=393) were female; BMI 38.26.7kg/m2, KCCQ-CSS 53.518.5,

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Obesity Quality of Life 40

Wellnest

DECEMBER 11, 2023

Prevention of Opportunistic Infections: Reduced Opportunistic Infections: ART significantly lowers the risk of opportunistic infections, such as pneumonia, tuberculosis, and fungal infections, which can be life-threatening in individuals with compromised immune systems. million lives lost to HIV and an estimated 39.0

Quality of Life 52

Quality of Life Myocardial Infarction Public Health Arrhythmia 52

European Journal of Heart Failure

NOVEMBER 11, 2024

The main secondary study endpoints are all-cause mortality, cardiovascular mortality, incidence of implantable cardioverter-defibrillator (ICD) therapy, hospitalizations, quality of life, time to first ICD therapy, number of device-detected ventricular tachycardia/ventricular fibrillation episodes, left ventricular function, and exercise tolerance.

Heart Transplant 40

Heart Transplant Transplant Heart Failure Ablation 40

Journal of the American Heart Association

FEBRUARY 25, 2025

BackgroundSex differences in patients with hypertrophic cardiomyopathy have been elaborated by many studies. This study evaluated sex disparities in a large Chinese cohort undergoing hypertrophic cardiomyopathy surgery.MethodsThe cohort encompassed 1613 patients, including 627 (38.9%) women who underwent septal myectomy between 2009 and 2018.ResultsAt

Cardiomyopathy 45

Cardiomyopathy Quality of Life Outcomes 45